Nonadherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey

Letter Dermatology

A survey of psoriasis patients on biologics during COVID-19: a single centre experience

Martina Burlando et al.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

Article Dermatology

Adherence to systemic therapy in patients with psoriasis during the COVID-19 pandemic: A multicenter study

Ilteris Oguz Topal et al.

Summary: During the COVID-19 pandemic, adherence to oral and injection therapies was relatively high among patients with psoriasis. However, disease severity and duration of medication use had a negative impact on treatment adherence.

JOURNAL OF COSMETIC DERMATOLOGY (2022)

添加到收藏夹

Article Dermatology

The impact of COVID-19 pandemic on psoriasis patients, and their immunosuppressive treatment: a cross-sectional multicenter study from Turkey

Selda Pelin Kartal et al.

Summary: This study evaluates the impact of the pandemic on psoriasis patients treated with immunosuppressive drugs. The results show that psoriasis patients using systemic immunosuppressive drugs do not have a higher, but even lower COVID-19 risk than the general population, and treatment compliance with biological drugs is higher.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

添加到收藏夹

Letter Dermatology

Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: A retrospective matched cohort study from Massachusetts

Vartan Pahalyants et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

添加到收藏夹

Article Rheumatology

Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform

Brian MacKenna et al.

Summary: This study aimed to assess the risk of severe COVID-19 outcomes in adults with immune-mediated inflammatory diseases and on immune-modifying therapies. The findings showed that adults with immune-mediated inflammatory diseases had an increased risk of COVID-19-related death, critical care admission or death, and hospital admission compared to the general population, but most targeted immune-modifying drugs did not increase the risk of adverse COVID-19 outcomes.

LANCET RHEUMATOLOGY (2022)

添加到收藏夹

Review Rheumatology

Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis

Shintaro Akiyama et al.

Summary: Patients with autoimmune diseases have a higher risk of COVID-19, primarily due to glucocorticoid use. Monotherapy with b/tsDMARDs is associated with a lower risk of hospitalisation and death.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Allergy

Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study

Satveer K. Mahil et al.

Summary: The study found that psoriasis patients using biologic therapy had a lower risk of hospitalization compared to those using nonbiologic therapy; older age, male sex, nonwhite ethnicity, and comorbidities were independent factors associated with higher hospitalization rates.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

添加到收藏夹

Article Dermatology

Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey

S. K. Mahil et al.

Summary: Research surveys indicate that individuals with IMIDs undergoing targeted systemic therapies tend to exhibit more stringent risk-mitigating behavior, potentially explaining their lower adverse outcomes during the COVID-19 pandemic. Additionally, shielding behavior is associated with risk factors for severe COVID-19, and there are modest variations in behavior observed across different nations.

BRITISH JOURNAL OF DERMATOLOGY (2021)

添加到收藏夹

Article Dermatology

The impact of COVID-19 in patients with psoriasis: A multicenter study in Istanbul

Asude Kara Polat et al.

Summary: During the COVID-19 pandemic, it was found that psoriasis patients had an equal distribution of male and female, with the majority unable to communicate with their physicians. Majority of these patients did not contract COVID-19, and there was no significant difference in hospitalization rates between psoriasis patients using biologics and those who did not. Psoriasis patients did not exhibit an increased risk of COVID-19 infection due to biologics usage.

DERMATOLOGIC THERAPY (2021)

添加到收藏夹

Article Dermatology

Biologic Therapies, Psoriasis, and COVID-19: Our Experience at the Psoriasis Unit of the University of Naples Federico II

Elisa Camela et al.

DERMATOLOGY (2021)

添加到收藏夹

Review Dermatology

Psoriasis: Recent progress in molecular-targeted therapies

Masaru Honma et al.

Summary: Psoriasis is a complex inflammatory skin disease characterized by scaly reddish plaques, but recent advances in molecular-targeted therapies offer excellent treatment options for even the most severe symptoms.

JOURNAL OF DERMATOLOGY (2021)

添加到收藏夹

Article Dermatology

National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments

Joel M. Gelfand et al.

Summary: This study updated guidance for managing psoriatic disease during the COVID-19 pandemic, with 22 original statements and 5 new recommendations. Results showed high consensus for 13 statements and moderate consensus for 14 statements. However, there are limitations in the evidence behind the guidance statements, with variable quality and quantity.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

添加到收藏夹

Review Clinical Neurology

A systematic review of the prevalence of anxiety among the general population during the COVID-19 pandemic

Fatemeh Pashazadeh Kan et al.

Summary: This study reviewed literature on anxiety prevalence during the COVID-19 pandemic, finding a prevalence of 27.3% among the general population and 39.6% among COVID-19 patients. Anxiety was higher in females and older adults, with Europe and Africa showing the highest rates. By identifying those at higher risk, targeted mental health services can be provided during the outbreak.

JOURNAL OF AFFECTIVE DISORDERS (2021)

添加到收藏夹

Article Rheumatology

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Anja Strangfeld et al.

Summary: Factors associated with COVID-19-related death in people with rheumatic diseases include age, sex, comorbidities, disease activity, and specific medications. Adequate disease control with disease-modifying anti-rheumatic drugs (DMARDs) without increasing glucocorticoid dosages is important, while caution may be required with certain medications such as rituximab and sulfasalazine.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic

Damian F. Santomauro et al.

Summary: This study aimed to quantify the impact of the COVID-19 pandemic on the prevalence and burden of major depressive disorder and anxiety disorders globally in 2020. The findings showed that the pandemic led to increased prevalence of major depressive disorder and anxiety disorders, with females and younger age groups being more affected. The pandemic has created an increased urgency to strengthen mental health systems in most countries and mitigation strategies are needed to address the burden of these mental disorders.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Development and validation of multivariable prediction models for adverse COVID-19 outcomes in patients with IBD

John Sperger et al.

Summary: This study developed an individualised prognostic risk prediction tool for predicting adverse COVID-19 outcomes in patients with inflammatory bowel disease (IBD) using data from an international registry. The models showed excellent discrimination and can effectively predict higher risk for COVID-19-related adverse outcomes in this population, aiding in discussions of risks with healthcare providers.

BMJ OPEN (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Psoriasis: a brief overview

Antony Raharja et al.

Summary: Psoriasis is a clinically heterogeneous skin disease with a major genetic component, requiring a holistic and multidisciplinary care approach. Treatments include topical agents, phototherapy, standard systemic drugs, biologics, and small molecule inhibitors, with advances in understanding its pathophysiology leading to the development of highly effective and targeted treatments.

CLINICAL MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19

Zara Izadi et al.

Summary: In this cohort study, TNF inhibitor monotherapy was associated with a lower risk of adverse COVID-19 outcomes compared with other commonly prescribed immunomodulatory treatment regimens among individuals with IMIDs.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Review Medicine, General & Internal

Biologics for Psoriasis during the COVID-19 Pandemic

Koji Kamiya et al.

Summary: Psoriasis is a chronic inflammatory disease that mainly affects the skin and joints, but recent therapeutic advancements, particularly biologics, have significantly improved treatment outcomes. During the COVID-19 pandemic, the use of biologics for psoriasis treatment appears to have some benefits against COVID-19 infection, emphasizing the importance of shared decision-making based on updated information.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Letter Dermatology

Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study

S. K. Mahil et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

添加到收藏夹

Article Dermatology

Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course

Basak Yalici-Armagan et al.

Summary: This study aimed to assess the treatment continuity, psoriasis courses, and COVID-19 features in patients treated with biological agents for psoriasis during the early phase of the pandemic. Most patients continued their treatment, with a significant proportion experiencing recurrence and exacerbation when they interrupted treatment. However, no patients were diagnosed with COVID-19 during the study period, supporting the importance and safety of continuing biological treatments for psoriasis in the COVID-19 era.

JOURNAL OF COSMETIC DERMATOLOGY (2021)

添加到收藏夹

Review Dermatology